Close Menu

financial results

Its revenues on an equivalent basis were up around 2 percent when excluding assets that were divested including Focus' products business.

The Swiss firm also reported an 8 percent year-over-year increase in diagnostics sales in the second quarter at constant exchange rates.

Abbott's MDx sales were driven by continued strong growth in its infectious disease testing business but were partly offset by the planned scale down of its genetics business.

Molecular biology sales rose 38 percent, driven by €52 million in Q2 sales of the firm's FilmArray molecular diagnostic products.

Contributing to the growth was a 16 percent increase in revenues from Enzo's clinical lab services division, which includes its molecular diagnostics offerings.

Following a partial response to Abbott's request to audit its books, Alere said it is confident the transaction will be completed.

Natera said that a greater proportion of NIPTs for average-risk pregnancies are being reimbursed, while reimbursement for microdeletion testing is declining. 

The company's first quarter revenues jumped due to an increase in NIPT and carrier screening testing volumes. 

Alere also said that some of its creditors have agreed to waive defaults arising from its delay in filing its 2015 earnings report, though others have already filed default notices.

On an organic basis, Q1 revenues grew more than 11 percent, driven in part by strong sales of its FilmArray, Vidas, and Vitek product portfolios.